Scapa continues to deliver positive results, ahead of expectations, despite the generally subdued economic environment. In Healthcare, strong progress continues with a 6 year contract extension with Convatec confirming the success of the strategy to become the turnkey supplier of choice in global healthcare. In Industrial, efficiency gains and asset optimisation continue to positively affect the margin. Momentum is strong and we continue to see the potential for strong growth opportunities, both organic and acquisitive, to drive earnings and share price upside. We have upgraded FY16 forecasts by c.6% and expect further forecast upside at the time of the finals in May.
